Intranasal Drug Delivery: How, Why and What for?
Open accessThe DOI matches its Crossref record; 174 of the 175 references it cites were found in a registry or an index.
Abstract
Over the last decade the interest in intranasal delivery as a non-invasive route for drug administration has been exponentially increased. Since the nasal mucosa offers numerous benefits as a target issue for drug delivery, a wide variety of therapeutic compounds may be administered intranasally for topic, systemic and central nervous system action. The present paper reviews the relevant aspects of nasal anatomy, physiology and histology, and refers to the biological, physicochemical and pharmaceutical factors that must be considered during the process of discovery and development of nasal drugs as well as in their incorporation in appropriate nasal pharmaceutical formulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is non-invasive, painless, non-stressful, and relatively easy to perform without requiring a medical specialist [246,247,248].”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [248]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Introduction and General Overview of Cyclodextrin Chemistry
Szejtli, J. (1998) · Chemical Reviews · doi:10.1021/cr970022c · Cited by 5,016
Chitosan Chemistry and Pharmaceutical Perspectives
Kumar, M. N. V. R., Muzzarelli, R. A. A., Muzzarelli, C., Sashiwa, H., & Domb, A. J. (2004) · Chemical Reviews · doi:10.1021/cr030441b · Cited by 2,938
Encyclopedia of Pharmaceutical Technology
Swarbrick, J. (2013) · CRC Press eBooks · doi:10.1201/b19309 · Cited by 1,794
Encyclopedia of pharmaceutical technology
(2003) · Choice Reviews Online · doi:10.5860/choice.40-6157 · Cited by 1,743
Abramson, M. H. (1996) · The Endocrinologist · doi:10.1097/00019616-199603000-00014 · Cited by 1,400
The Lung: Scientific Foundations
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-6-503_2 · Cited by 1,190
Nasal drug delivery—possibilities, problems and solutions
Illum, L. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00363-2 · Cited by 1,102
Thorne, R. G., Pronk, G. J., Padmanabhan, V., & Frey, W. H. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.05.029 · Cited by 958
Transport of drugs from the nasal cavity to the central nervous system
Illum, L. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00087-7 · Cited by 907
Hanson, L. R., & Frey, W. H. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s3-s5 · Cited by 697
Research works printed but not linked: 5
- [27]27. Stevens A., Lowe J., Human histology, Mosby, Philadelphia, USA, 1997.
- [35]35. Dae-Duk Ki, Drug Absorption Studies: In situ, In vitro and In silico models, chapter 9, Springer, USA, 2007.
- [56]56. Varshosaz J, Sadrai H, Heidari A. Nasal delivery of insulin using bioadhesive chitosan gels. Drug Deliv, 2006; 13:31-38.
- [72]72. Belshe RB, Newman FK, Anderson EL, Wright PF, Karron RA, Tollefson S, Henderson FW, Meissner HC, Madhi S, Roberton D, Marshall H, Loh R, Sly P, Murphy B, Tatem JM, Randolph V, Hackell J, Gruber W, Tsai TF. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus in infants and young children. J Infect Dis, 2004; 190:2096-2103.
- [113]113. Hussain A.A., Bawarshi-Nassar R., Huang C.H., Transnasal Systemic Medications. Elsevier, Amsterdam, 1985. 123.
Cited by
Items 101–200 of 661
Noninvasive vaccination against infectious diseases
Zheng, Z., Díaz-Arévalo, D., Guan, H., & Zeng, M. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1461296 · Cited by 85
Imaging of intranasal drug delivery to the brain.
Veronesi, M. C., Alhamami, M., Miedema, S. B., Yun, Y., Ruiz-Cardozo, M. A., & Vannier, M. W. (2020) · PubMed · Cited by 111
Optimization of Curcumin Nanocrystals as Promising Strategy for Nose-to-Brain Delivery Application
Bonaccorso, A., Gigliobianco, M. R., Pellitteri, R., Santonocito, D., Carbone, C., Martino, P. D., Puglisi, G., & Musumeci, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12050476 · Cited by 84
Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer’s disease
Taliyan, R., Kakoty, V., Sarathlal, K. C., Kharavtekar, S. S., Karennanavar, C. R., Choudhary, Y. K., Singhvi, G., Riadi, Y., Dubey, S. K., & Kesharwani, P. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.044 · Cited by 80
Nanoneurotherapeutics approach intended for direct nose to brain delivery
Md, S., Mustafa, G., Baboota, S., & Ali, J. (2015) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2015.1052081 · Cited by 78
Development and Evaluation of a Novel Intranasal Spray for the Delivery of Amantadine
Lungare, S., Bowen, J., & Badhan, R. K. S. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.12.016 · Cited by 86
Advances in nasal trans-mucosal drug delivery
Keshari, R. K. (2011) · Cited by 77
Kulvanich, P., Sinsuebpol, C., & Chatchawalsaisin, J. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s47681 · Cited by 77
Focused ultrasound-enhanced intranasal brain delivery of brain-derived neurotrophic factor
Chen, H., Yang, G. Z. X., Getachew, H., Acosta, C., Sierra Sánchez, C., & Konofagou, E. E. (2016) · Scientific Reports · doi:10.1038/srep28599 · Cited by 75
Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Development of a CFD Model
Rygg, A. D., & Longest, P. W. (2016) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2015.1252 · Cited by 79
Nanoemulsion: An Advanced Vehicle For Efficient Drug Delivery
Ali, A., Ansari, V. A., Ahmad, U., Akhtar, J., & Jahan, A. (2017) · Drug Research · doi:10.1055/s-0043-115124 · Cited by 89
Min, S. K., Park, J. S., Luo, L., Kwon, Y. S., Lee, H. C., Jung Shim, H., Kim, I.-D., Lee, J.-K., & Shin, H. S. (2015) · Scientific Reports · doi:10.1038/srep14418 · Cited by 74
Sita, V. G., Jadhav, D., & Vavia, P. R. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101791 · Cited by 88
In vitro – in vivo correlation of intranasal drug deposition
Guellec, S. L., Ehrmann, S., & Vecellio, L. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.09.002 · Cited by 74
Nanotechnologies for intranasal drug delivery: an update of literature
Lombardo, R., Musumeci, T., Carbone, C., & Pignatello, R. (2021) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2021.1950186 · Cited by 79
Intranasal delivery of therapeutic proteins for neurological diseases
Malerba, F., Paoletti, F., Capsoni, S., & Cattaneo, A. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.588204 · Cited by 73
Central Nervous System Control of Glucose Homeostasis: A Therapeutic Target for Type 2 Diabetes?
Mirzadeh, Z., Faber, C. L., & Schwartz, M. W. (2022) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052220-010446 · Cited by 76
Alam, M. I., Baboota, S., Ahuja, A., Ali, M., Ali, J., & Sahni, J. K. (2013) · Drug Delivery · doi:10.3109/10717544.2013.822945 · Cited by 73
Safety considerations in the management of allergic diseases: focus on antihistamines
Yanai, K., Rogala, B., Chugh, K., Paraskakis, E., Pampura, A. N., & Boev, R. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.672405 · Cited by 78
Yusuf, M., Khan, M., Alrobaian, M. M., Alghamdi, S. A., Warsi, M. H., Sultana, S., & Khan, R. A. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102214 · Cited by 72
Pitta, S. K., Dudhipala, N. R., Narala, A., & Veerabrahma, K. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1402918 · Cited by 73
Hogan, R. E., Gidal, B. E., Koplowitz, B., Koplowitz, L. P., Lowenthal, R. E., & Carrazana, E. J. (2020) · Epilepsia · doi:10.1111/epi.16449 · Cited by 72
Tada, R., Hidaka, A., Iwase, N., Takahashi, S., Yamakita, Y., Iwata, T., Muto, S., Sato, E., Takayama, N., Honjo, E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139785 · Cited by 72
Charalambous, M., Bhatti, S. F. M., Ham, L. V., Platt, S. R., Jeffery, N. D., Tipold, A., Siedenburg, J. S., Volk, H. A., Hasegawa, D., Gallucci, A., et al. (2017) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.14734 · Cited by 72
Nose-to-brain delivery of levetiracetam after intranasal administration to mice
Gonçalves, J., Bicker, J., Gouveia, F., Liberal, J. M. T., Oliveira, R. C., Alves, G., Falcão, A. C., & Fortuna, A. C. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.04.047 · Cited by 72
Self-citationRamvikas, M., Arumugam, M., Chakrabarti, S. R., & Jaganathan, K. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-39981-4.00015-4 · Cited by 71
Facilitation of Drug Transport across the Blood–Brain Barrier with Ultrasound and Microbubbles
Meairs, S. (2015) · Pharmaceutics · doi:10.3390/pharmaceutics7030275 · Cited by 67
Opportunities and challenges for the nasal administration of nanoemulsions
Comfort, C., Garrastazu, G., Pozzoli, M., & Sonvico, F. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150108144655 · Cited by 69
In Vitro Anatomical Models for Nasal Drug Delivery
Williams, G., & Suman, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071353 · Cited by 70
A New Brain Drug Delivery Strategy: Focused Ultrasound-Enhanced Intranasal Drug Delivery
Chen, H., Chen, C., Acosta, C., Wu, S.-Y., Sun, T., & Konofagou, E. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108880 · Cited by 78
Particles and powders: Tools of innovation for non-invasive drug administration
Buttini, F., Colombo, P., Rossi, A., Sonvico, F., & Colombo, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.02.028 · Cited by 70
Lu, T., Jiang, Y., Zhou, Z., Yue, X., Wei, N., Chen, Z., Ma, M., Xu, G., & Liu, X. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1319 · Cited by 70
Review of Intranasally Administered Medications for Use in the Emergency Department
Bailey, A. M., Baum, R. A., Horn, K. S., Lewis, T., Morizio, K. M., Schultz, A. E., Weant, K. A., & Baker, S. N. (2017) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2017.01.020 · Cited by 80
Nose-to-brain delivery of antipsychotics using nanotechnology: a review
Tan, M. S. A., Parekh, H. S., Pandey, P. M., Siskind, D. J., & Falconer, J. R. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1762563 · Cited by 72
Fu, Q., Shin, H., Lee, B., & Han, H. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.04.007 · Cited by 68
Spray dried powders for nasal delivery: Process and formulation considerations
Henriques, P., Fortuna, A. C., & Doktorovová, S. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.05.002 · Cited by 74
Self-citationEfficacy of Viola odorata in Treatment of Chronic Insomnia
Feyzabadi, Z., Jafari, F., Kamali, S. H., Ashayeri, H., Aval, S. B., Esfahani, M. M., & Sadeghpour, O. (2014) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.17511 · Cited by 66
Barriers to Liposomal Gene Delivery: from Application Site to the Target.
Saffari, M., Moghimi, H. R., & Dass, C. R. (2016) · PubMed Central · Cited by 79
Ahmad, N., Ahmad, R., Alam, A., & Ahmad, F. J. (2018) · Drug Research · doi:10.1055/a-0596-7288 · Cited by 69
Oxytocin modulates behavioral and physiological responses to a stressor in marmoset monkeys
Cavanaugh, J., Carp, S. B., Rock, C. M., & French, J. A. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.12.027 · Cited by 64
“Peptides administered intranasally are quickly absorbed into the bloodstream via the nasal passage (Pires et al., 2009), and some fraction of the peptides appear to bypass the blood-brain barrier (BBB) to access the central nervous system (CNS) via the olfactory bulb and the maxillary branch of the…”
BackgroundAlberto, M., Paiva‐Santos, A. C., Veiga, F., & Pires, P. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122742 · Cited by 74
Xiao, X.-Y., Zhu, Y., Bu, J., Li, G.-W., Zhou, J., & Zhou, S. (2016) · BioMed Research International · doi:10.1155/2016/2571060 · Cited by 65
Microbubble-Assisted Ultrasound for Drug Delivery in the Brain and Central Nervous System
Burgess, A., & Hynynen, K. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-22536-4_16 · Cited by 62
Chin, L. Y., Tan, J. Y. P., Choudhury, H., Pandey, M., Sisinthy, S. P., & Gorain, B. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102341 · Cited by 66
Huang, G., Xie, J., Shuai, S., Wei, S., Chen, Y., Guan, Z., Zheng, Q., Yue, P., & Wang, C. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120182 · Cited by 60
Intranasal therapies for acute seizures
Kälviäinen, R. K. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.04.027 · Cited by 61
Chitosan-Based Multifunctional Platforms for Local Delivery of Therapeutics
Hong, S., Yoo, S., Kim, H., & Lee, J. (2017) · Marine Drugs · doi:10.3390/md15030060 · Cited by 63
Delivery of Nanoparticles and Macromolecules across the Blood–Brain Barrier
Nowak, M., Helgeson, M. E., & Mitragotri, S. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900073 · Cited by 60
Iota-carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell culture
Bansal, S., Jonsson, C. B., Taylor, S. L., Figueroa, J. M., Dugour, A. V., Palacios, C., & Vega, J. C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259943 · Cited by 59
Quality by Design approach for an in situ gelling microemulsion of Lorazepam via intranasal route
Shah, V., Sharma, M. K., Pandya, R., Parikh, R. K., Bharatiya, B., Shukla, A. D., & Tsai, H. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.03.002 · Cited by 61
Cloyd, J. C., Haut, S. R., Carrazana, E. J., & Rabinowicz, A. L. (2021) · Epilepsia · doi:10.1111/epi.16847 · Cited by 59
Shah, B. M., Khunt, D., Misra, M., & Padh, H. (2018) · Pharmaceutical Research · doi:10.1007/s11095-017-2279-z · Cited by 60
Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges
Bai, Z., Wan, D., Lan, T., Hong, W., Dong, H., Wei, Y., & Wei, X. (2024) · ACS Nano · doi:10.1021/acsnano.3c10797 · Cited by 60
Intranasal delivery of antipsychotic drugs
Katare, Y. K., Piazza, J. E., Bhandari, J., Daya, R. P., Akilan, K., Simpson, M. J., Hoare, T. R., & Mishra, R. K. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.11.027 · Cited by 62
Nojoki, F., Ebrahimi-Hosseinzadeh, B., Hatamian-Zarmi, A., Khodagholi, F., & Khezri, K. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113450 · Cited by 61
Esposito, E., Ravani, L., Drechsler, M., Mariani, P., Contado, C., Ruokolainen, J., Ratano, P., Campolongo, P., Trezza, V., Nastruzzi, C., et al. (2014) · Materials Science and Engineering C · doi:10.1016/j.msec.2014.12.012 · Cited by 58
Prediction of nasal spray drug absorption influenced by mucociliary clearance
Shang, Y., Inthavong, K., Qiu, D., Singh, N. P., He, F., & Tu, J. Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246007 · Cited by 56
The Use of Solid Lipid Nanoparticles for Sustained Drug Release
Attama, A. A., & Umeyor, C. E. (2015) · Therapeutic Delivery · doi:10.4155/tde.15.23 · Cited by 59
Nasal vaccines: solutions for respiratory infectious diseases
Nakahashi-Ouchida, R., Fujihashi, K., Kurashima, Y., Yuki, Y., & Kiyono, H. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.10.009 · Cited by 57
Erythropoietin: A Neuroprotective Agent in Cerebral Hypoxia, Neurodegeneration, and Epilepsy
Merelli, A., Czornyj, L. A., & Lazarowski, A. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319380011 · Cited by 61
Development of a computational fluid dynamics model for mucociliary clearance in the nasal cavity
Shang, Y., Inthavong, K., & Tu, J. Y. (2019) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2019.01.015 · Cited by 55
Papakyriakopoulou, P., Manta, K., Kostantini, C., Kikionis, S., Banella, S., Ioannou, E., Christodoulou, E., Rekkas, D. M., Dallas, P. P., Vertzoni, M., et al. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121016 · Cited by 55
Cirri, M., Maestrelli, F., Nerli, G., Mennini, N., D’Ambrosio, M., Luceri, C., & Mura, P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13070969 · Cited by 52
Balde, A., Kim, S., Benjakul, S., & Nazeer, R. A. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.09.116 · Cited by 52
Development of Nasal Vaccines and the Associated Challenges
Nian, X., Zhang, J., Huang, S., Duan, K., Li, X., & Yang, X. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14101983 · Cited by 58
Suitability of RPMI 2650 cell models for nasal drug permeability prediction
Sibinovska, N., Žakelj, S., & Kristan, K. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.10.008 · Cited by 55
Haasbroek‐Pheiffer, A., Niekerk, S. E. V., van der Kooy, F., Cloete, T. T., Steenekamp, J. H., & Hamman, J. H. (2023) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2348 · Cited by 55
Wheless, J. W., Meng, T., Ess, P. J. V., Detyniecki, K., Sequeira, D. J., & Pullman, W. E. (2019) · Epilepsia · doi:10.1111/epi.16300 · Cited by 51
Pentón-Rol, G., Marín-Prida, J., & Falcón-Cama, V. (2018) · Behavioral Sciences · doi:10.3390/bs8010015 · Cited by 50
Fréchou, M., Zhang, S., Lière, P., Delespierre, B., Soyed, N., Pianos, A., Schumacher, M., Mattern, C., & Guennoun, R. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.06.002 · Cited by 52
Dehghan, S., Tafaghodi, M., Bolourieh, T., Mazaheri, V., Torabi, A., Abnous, K., & Kheiri, M. T. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.08.032 · Cited by 50
Rygg, A. D., Hindle, M., & Longest, P. W. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.03.033 · Cited by 52
Development of Nasal Lipid Nanocarriers Containing Curcumin for Brain Targeting
Vaz, G. R., Hädrich, G., Bidone, J., Rodrigues, J. L., Falkembach, M. C., Putaux, J.-L., Hort, M. A., Monserrat, J. M., Varela Junior, A. S., Teixeira, H. F., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160355 · Cited by 50
Rabinowicz, A. L., Carrazana, E. J., & Maggio, E. (2021) · Drugs in R&D · doi:10.1007/s40268-021-00360-5 · Cited by 52
Study of Valproic Acid Liposomes for Delivery into the Brain Through an Intranasal Route
Yuwanda, A., Surini, S., Harahap, Y., & Jufri, M. (2021) · Heliyon · doi:10.1016/j.heliyon.2022.e09030 · Cited by 56
Optimal Volume of Administration of Intranasal Midazolam in Children: A Randomized Clinical Trial
Tsze, D. S., Ieni, M., Fenster, D. B., Babineau, J., Kriger, J., Levin, B., & Dayan, P. S. (2016) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2016.08.450 · Cited by 50
Sosnik, A., Seremeta, K. P., Imperiale, J. C., & Chiappetta, D. A. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.655268 · Cited by 46
Nanomedicines in the Management of Alzheimer’s Disease: Current View and Future Prospects
Chopra, H., Bibi, S., Singh, I., Kamal, M. A., Islam, F., Alhumaydhi, F. A., Emran, T. B., & Cavalu, S. D. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.879114 · Cited by 49
Fonseca‐Santos, B., da Silva, P. B., Rigon, R. B., Sato, M. R., & Chorilli, M. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867326666190624155938 · Cited by 53
Chen, K. H., Sabatino, M. D., Albertini, B., Passerini, N., & Kett, V. L. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.07.006 · Cited by 47
Rygg, A. D., Hindle, M., & Longest, P. W. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1837-5 · Cited by 48
High efficiency intranasal drug delivery using Intravail® alkylsaccharide absorption enhancers
Maggio, E., & Pillion, D. J. (2012) · Drug Delivery and Translational Research · doi:10.1007/s13346-012-0069-z · Cited by 47
Javia, A., & Thakkar, H. P. (2017) · Journal of Microencapsulation · doi:10.1080/02652048.2017.1375038 · Cited by 49
Current and New Approaches for Mucosal Vaccine Delivery
Rhee, J. H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-811924-2.00019-5 · Cited by 54
Maeng, J., & Lee, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1068495 · Cited by 47
Overcoming Barriers in Glioblastoma—Advances in Drug Delivery Strategies
ter Linden, E., Abels, E. R., van Solinge, T. S., Neefjes, J., & Broekman, M. L. D. (2024) · Cells · doi:10.3390/cells13120998 · Cited by 52
Li, B. V., Jin, F., Lee, S. L., Bai, T., Chowdhury, B. A., Caramenico, H. T., & Conner, D. P. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9494-2 · Cited by 45
Heydarirad, G., Keyhanmehr, A. S., Mofid, B., Nikfarjad, H., & Mosavat, S. H. (2019) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2019.01.017 · Cited by 47
Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients
Jin, Z., Han, Y., Zhang, D., Li, Z., Jing, Y., Hu, B., & Sun, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102070 · Cited by 48
Intranasal delivery: circumventing the iron curtain to treat neurological disorders
Jiang, Y., Li, Y., & Liu, X. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1065812 · Cited by 43
Strategies for Enhanced Peptide and Protein Delivery
McCrudden, M., Singh, T. R. R., Migalska, K., & Donnelly, R. F. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.31 · Cited by 47
Nasal route: an alternative approach for antiemetic drug delivery
Özsoy, Y., & Güngör, S. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.607437 · Cited by 44
Vellecco, V., Saviano, A., Raucci, F., Casillo, G. M., Mansour, A. A., Panza, E., Mitidieri, E., Femminella, G. D., Ferrara, N., Cirino, G., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106595 · Cited by 49
Wei, S., Zhai, Z., Kong, X., Wu, C., Zhu, B., Zhao, Z., & Zhang, X. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125584 · Cited by 48
Chitosan-based nanomedicine for brain delivery: Where are we heading?
Pacheco, C., Sousa, F., & Sarmento, B. F. C. C. (2019) · Reactive and Functional Polymers · doi:10.1016/j.reactfunctpolym.2019.104430 · Cited by 47
Itokazu, Y., Fuchigami, T., Morgan, J. C., & Yu, R. K. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.005 · Cited by 45
Oxytocin regulates reunion affiliation with a pairmate following social separation in marmosets
Cavanaugh, J., Mustoe, A. C., & French, J. A. (2018) · American Journal of Primatology · doi:10.1002/ajp.22750 · Cited by 43
A review on factors affecting the design of nasal drug delivery system
Dhakar, R. C., Maurya, S. D., Tilak, V. K., & Gupta, A. K. (2011) · International Research Journal of Pharmacy · Cited by 42
Chhabra, R., Gupta, R., & Gupta, L. K. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.108390 · Cited by 42
Novel Mucoadhesive Polymers for Nasal Drug Delivery
Anand, U., Feridooni, T., & Agu, R. U. (2012) · InTech eBooks · doi:10.5772/52560 · Cited by 45
Metadata
- Authors
- Pires, A., Fortuna, A., Alves, G., & Falcão, A.
- Affiliations
- University of Coimbra (PT)
- University of Beira Interior (PT)
- Venue
- Journal of Pharmacy & Pharmaceutical Sciences
- Publisher
- Frontiers Media SA
- Published
- 2009-10-12
- Volume
- 12
- Issue
- 3
- Pages
- 288
- ISSN
- 1482-1826 (ISSN-L)
- OpenAlex
- W2106536537
- Cited by
- 641
- References
- 175
- Citations by year
- 2026: 31 · 2025: 49 · 2024: 44 · 2023: 45 · 2022: 67 · 2021: 65 · 2020: 48 · 2019: 41 · 2018: 35 · 2017: 42 · 2016: 35 · 2015: 29 · 2014: 32 · 2013: 25 · 2012: 23
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Pharmacy & Pharmaceutical Sciences (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by-sa)
- Funders
- Fundação para a Ciência e a Tecnologia (SFRH/BD/45145/2008)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Health Sciences › Medicine › Otorhinolaryngology › Sinusitis and nasal conditions
- Keywords
- intranasal drug delivery, nasal mucosa, transmucosal drug absorption, brain drug delivery, topical drug delivery, systemic drug delivery
- MeSH terms
- Absorption, Administration, Intranasal, Animals, Biological Availability, Humans, Nasal Cavity, Nasal Mucosa, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.